Asset Details
Do you wish to reserve the book?
Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity
Do you wish to request the book?
Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity
2026
Overview
Tumor‐associated immunosuppressive neutrophils, termed polymorphonuclear myeloid‐derived suppressor cells (PMN‐MDSCs), compromise cancer immunotherapy. Emerging evidence indicates that neutrophil fate can be programmed as early as the hematopoietic stem and progenitor cell (HSPC) stage. Reprogramming HSPCs toward antitumor neutrophils offers a promising therapeutic strategy. Here, we demonstrate that an albumin‐bound STING agonist (Nano ZSA‐51D) reprograms HSPCs to generate antitumor neutrophils, enhancing MHC I‐mediated CD8+ T cell immunity and sensitizing tumors to α‐PD1 immunotherapy. Nano ZSA‐51D expands HSPCs and reprograms them toward granulocyte‐monocyte progenitors for neutrophil development. It further converts immature (CD101−) and mature (CD101+) neutrophils into a CD14+ICAM‐1+ subset through STING‐NF‐κB–TNF‐α signaling, enhancing tumor infiltration and antitumor activity. These neutrophils upregulate interferon signaling and MHC I antigen presentation, thereby boosting tumor‐specific CD8+ T cell responses. Notably, both adoptive transfer of Nano ZSA‐51D‐reprogrammed neutrophils and systemic Nano ZSA‐51D treatment synergizes with α‐PD1 therapy to achieve complete remission of colon tumors through neutrophil‐ and CD8+ T cell‐dependent mechanisms, with potent efficacy also validated in otherwise immune‐resistant pancreatic cancer models. Our findings establish a therapeutic strategy to reprogram HSPCs toward antitumor neutrophils, highlighting the potential of targeting early hematopoiesis to rewire neutrophil fate in cancer immunotherapy. This study demonstrates that an albumin‐bound STING agonist (Nano ZSA‐51D) reprograms HSPCs to produce antitumor neutrophils with enhanced MHC I–mediated CD8+ T cell activation, thereby sensitizing tumors to α‐PD1 therapy. These findings highlight a strategy to target early hematopoiesis for shaping neutrophil fate and potentiating cancer immunotherapy.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Animals
/ Cancer
/ CD8-Positive T-Lymphocytes - drug effects
/ CD8-Positive T-Lymphocytes - immunology
/ hematopoietic stem and progenitor cells
/ Hematopoietic Stem Cells - drug effects
/ Hematopoietic Stem Cells - immunology
/ Hematopoietic Stem Cells - metabolism
/ Humans
/ Membrane Proteins - agonists
/ Membrane Proteins - metabolism
/ Mice
/ Tumors
